# Kisspeptin: The Neuropeptide That Switches On the Reproductive Hormone Axis > Kisspeptin is the KISS1 neuropeptide that drives the body's own reproductive hormone axis from the top. Plain-English, cited digests of the mechanism, the human studies, and the sexual-brain research. A field-notebook digest of what the studies actually measured — the pulse it sets, the desire circuits it modulates, and the limit it runs into — with every quantitative claim cited. ## The short version Kisspeptin is a small signaling molecule — a neuropeptide — that the brain uses to switch on the body's reproductive hormone system. It is made by the KISS1 gene and it acts at the very top of the chain: it tells certain brain cells to release GnRH (the hormone that starts the whole reproductive cascade), which then tells the pituitary gland to make LH and FSH, which finally tell the ovaries or testes to make the sex hormones. So kisspeptin is not a sex hormone itself, and it is not the same thing as GnRH — it sits one step above GnRH and turns it on. Researchers study it because flipping that switch cleanly has real uses: restarting missing menstrual cycles, triggering egg maturation in IVF more safely, and — the angle this site follows — changing how the brain processes sexual desire and attraction. It is investigational, meaning no health agency has approved it for anything yet. One quirk matters a lot: push it too hard or too constantly and the receptor stops responding within days. What people report, including the downsides, is on [the effects page](/effects). ## What is kisspeptin Kisspeptin is the protein product of the KISS1 gene, and it works by binding a receptor called KISS1R (an older name for it is GPR54) [4]. That receptor sits on the GnRH-releasing neurons in the hypothalamus — a region deep in the brain. When kisspeptin binds, those neurons fire and release GnRH in pulses, and the rest of the [kisspeptin peptide](/what-is-kisspeptin) cascade follows: GnRH to the pituitary, then luteinizing hormone (LH) and follicle-stimulating hormone (FSH), then the gonads. The single cleanest demonstration of how central it is came from genetics. People born with broken copies of the GPR54 gene fail to go through puberty, and mice engineered the same way reproduce that failure [4]. That finding, published in 2003, reframed kisspeptin overnight from a curiosity into the master upstream gatekeeper of the entire reproductive axis. It is also why the term "kisspeptin supplement" is misleading: kisspeptin is an investigational research peptide acting on a master neuroendocrine switch, not a dietary supplement, and it is not sold or regulated as one. ## What the human studies have measured In healthy men, a single intravenous dose of kisspeptin-10 raised luteinizing hormone from 4.1 to 12.4 IU/L within 30 minutes, and a continuous infusion lifted testosterone from 16.6 to 24.0 nmol/L [3]. In women whose periods had stopped from hypothalamic suppression, infused kisspeptin-54 roughly tripled the rate of LH pulses and increased the hormone released per pulse about six-fold [5]. In IVF, a single under-the-skin dose of kisspeptin-54 matured eggs in 95% of women at high risk of a dangerous over-response, with no case of moderate, severe, or critical ovarian hyperstimulation [6]. The lens this site follows is the brain. In 32 men with low sexual desire, intravenous kisspeptin-54 changed activity across the brain networks that process sexual cues and increased penile tumescence by up to 56% over placebo, alongside higher self-reported desire and no adverse events [8]. A companion trial in women with the same condition found kisspeptin modulated the brain's attraction and sexual-aversion circuitry [9]. These are study findings, measured in supervised trials. What individuals report on their own is a separate, anecdotal matter — kept apart on [the effects page](/effects). ## The limit built into the signal Kisspeptin's signal is pulsatile and self-limiting. A well-spaced dose produces a clean rise; continuous or high-dose exposure desensitizes the KISS1R receptor within days, and the response fades — a property called tachyphylaxis [12]. In one study, twice-daily injections saw the acute LH jump fall from about 24 IU/L on day one to roughly 2.5 IU/L by the fourteenth injection day [12]. Even high-dose continuous infusion showed the same blunting [5]. This is the defining honest fact about kisspeptin as a tool: the rhythm matters more than the amount. It also sets a hard boundary on the research. No kisspeptin product has FDA, EMA, or any other regulatory approval for any indication; every human study to date is Phase 1 or Phase 2, run under medical supervision with pharmaceutical-grade peptide [7]. Real-world anecdotal data is genuinely thin because it is investigational and not a sold consumer product. The pages here read the published record as it stands and mark where the human data stop. See the [Kisspeptin research](/research) for the full account. --- A field-notebook reading of the kisspeptin literature — the upstream-of-GnRH pulse it sets watched closely and recorded plainly, its sexual-brain findings kept apart from what people merely report; a place where the record is kept, never a clinic, a vendor, or a prescription.